Etoricoxib in the 21st Century: An Old Molecule With New Possibilities
Keywords:
etoricoxib, ankylosing spondylitis, acute gouty arthritis, back pain, osteoarthritis, rheumatoid arthritis, third molar extractionAbstract
Chronic pain conditions, including osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis (AS), and acute gouty arthritis (AGA) are responsible for a substantial proportion of global disabilities and healthcare burdens. Etoricoxib, a selective cyclooxygenase-2 (COX) inhibitor, has shown better efficacy in these conditions due to its anti-inflammatory and analgesic properties. Its pharmacokinetic properties allow for rapid absorption and a long half-life, the latter enabling once-daily dosing, which has the impact of enhancing both adherence and symptom relief. Recent pharmacological investigation has evidenced the efficacy etoricoxib intervention in cases of other indications such as dental pain, low back pain (LBP), and postoperative analgesia. Clinical trials and meta-analyses have revealed etoricoxib’s superiority over traditional non-steroidal anti- inflammatory drugs (NSAIDs) such as ibuprofen. Novel delivery systems like nanostructured lipid carriers have been proven with to have improved anti-inflammatory effects and decreased cardiotoxicity in preclinical studies. Etoricoxib has shown synergistic outcomes with combination therapies of etoricoxib with tramadol, pregabalin, or thiocolchicoside in the treatment of both acute as well as chronic musculoskeletal pain. This article assembles the latest therapeutic advances and clinical and safety information on etoricoxib, highlighting its emerging role as an important drug in personalized management of pain and inflammation.
References
Rice A, Smith B, Blyth F. Pain and the global burden of disease. Pain. 2016;157:791-6.
Mattos-Pereira G, Esteves-Lima R, Cota L, Alvarenga-Brant R, Costa F. Preemptive effects of etoricoxib, acetaminophen, nimesulide, and ibuprofen on postoperative pain management after single-implant surgery: A randomized clinical trial. Clin Oral Implants Res. 2023;34:1299-308.
He B shu, Wang J, Liu J, Hu X min. Eco-pharmacovigilance of non-steroidal anti-inflammatory drugs: Necessity and opportunities. Chemosphere. 2017;181:178-89.
Van Der Linden M, Van Der Bij S, Welsing P, Kuipers E, Herings R. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis. 2009;68:668-73.
Micklewright R, Lane S, Linley W, McQuade C, Thompson F, Maskrey N. NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors. Aliment Pharmacol Ther. 2003;17:321-32.
Stiller C, Hjemdahl P. Lessons from 20 years with COX-2 inhibitors: Importance of dose-response considerations and fair play in comparative trials. J Intern Med. 2022;292:557-74.
Swain G, Jain S, Gupta A, Pal D, Kumar N. Investigation of novel etoricoxib analogues as potential cox-ii inhibitors through a bioisosteric strategy, admet evaluations, docking studies, and molecular dynamics simulations. Curr Comput Aided Drug Des. 2025;21. PubMed PMID: 40598721.
Williams B, Buvanendran A. Nonopioid analgesics: NSAIDs, COX-2 inhibitors, and acetaminophen. Essentials Pain Med. 2011;130-9.
Gottesdiener K, Group for the P 007 S, Schnitzer T, Group for the P 007 S, Fisher C, Group for the P 007 S, et al. Results of a randomized, dose‐ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology. 2002;41:1052-61.
Jagannathan H, Thota A, B. Kumarappa AK, Kishore G. A comparative study of aceclofenac versus etoricoxib in the management of acute low back pain in a tertiary care hospital. J Drug Assess. 2020;9:60-5.
Pallay RM, Seger W, Adler JL, Ettlinger RE, Quaidoo EA, Lipetz R, et al. Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: A 3 month, randomized, controlled trial. Scand J Rheumatol. 2004;33:257-66.
Croom KF, Siddiqui MAA. Etoricoxib: A review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis. Drugs. 2009;69:1513-32.
Lin HY, Cheng TT, Wang JH, Lee CS, Chen MH, Lei V, et al. Etoricoxib improves pain, function and quality of life: Results of a real-world effectiveness trial. Int J Rheum Dis. 2010;13:144-50.
Birbara CA, Puopolo AD, Munoz DR, Sheldon EA, Mangione A, Bohidar NR, et al. Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: Improvement in pain and disability - A randomized, placebo-controlled, 3-month trial. J Pain. 2003;4:307–15.
Reginster JY, Malmstrom K, Mehta A, Bergman G, Ko AT, Curtis SP, et al. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis. 2007;66:945-51.
Chakravarthi S, Karthekeyan R, Gopalakrishna PK, David SR, Rajabalaya R. Anti-inflammatory mechanisms of selective Cox-2 inhibitors: a preclinical analysis. J Pharmacol Genet Mol Biol. 2025;01:34-48.
Yahya TA, Mousa YJ. Pharmacodynamic and Pharmacokinetic Comparison between Selective and Non-selective COX-2 Inhibitors in Mice. J Appl Vet Sci. 2024;9:99-105.
Gong L, Thorn CF, Bertagnolli MM, Grosser T, Altman RB, Klein TE. Celecoxib pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012;22:310-8.
He W, Wu Y, Liu Q, Cheng X, Wu J, Han X, et al. Effect of Etoricoxib on miR-214 and inflammatory reaction in knee osteoarthritis patients. Am J Transl Res. 2021; 13:9586. PubMed PMID: 34540082
Colceriu-Șimon IM, Feștilă D, Emoke H, Pancsur A, Șimon M Ștefania, Olteanu CD, et al. The effects of non-steroidal anti-inflammatory drugs used for orthodontic pain management on tooth movement: a comprehensive review of the literature. J Clin Med. 2025;14:2920. PubMed PMID: 40363952
Patrignani P, Capone ML, Tacconelli S. Clinical pharmacology of etoricoxib: a novel selectiveCOX2 inhibitor. Expert Opin Pharmacother. 2003;4:265-84.
Vasilchuk AG, Ivanova EA, Matyushkin AI, Alekseeva S V., Kachalov KS, Voronina TA. Effect of cyclooxygenase inhibitors etoricoxib and diclofenac sodium and their combinations with mexidol on blood pressure and hematological indices in rats. Moscow Univ Biol Sci Bull. 2022;77:18-24.
Zisis V, Papadopoulos P, Kyriakou N, Charisi C, Poulopoulos A. The occurrence of etoricoxib-induced stevens-johnson syndrome with oral manifestations in a female patient: a case study. Cureus. 2024;16. PubMed PMID: 39077250
Farooqui S, Shyma Z, Zulekha S, Martis J, V A V. Etoricoxib induced toxic epidermal necrolysis: a case report. Indian J Pharm Pract. 2024;17:89-92.
Akter B, Aishee S, Hridoy A, Pulok MMH, Islam MA, Biswas A, et al. Structural tailoring of etoricoxib: A spectrochemical, medicinal and pharmacological study. Chem Phys Impact. 2025;10:100830.
Capone ML, Tacconelli S, Patrignani P. Clinical pharmacology of etoricoxib. Expert Opin Drug Metab Toxicol. 2005;1:269-82.
Shah J, Kotadiya R. A critical review on analytical methods for recently approved fdc drugs: pregabalin and etoricoxib. Crit Rev Anal Chem. 2022;52:1048-68.
Clarke R, Derry S, Moore RA. Single dose oral etoricoxib for acute postoperative pain in adults. Cochrane Database Syst Rev. 2014;2014:CD004309. PubMed PMID: 24809657
Directorate General of Central Drugs Standard Control Organization (India). Fixed-dose combinations approved by DCG(I) since 1961 to 31 December 2019 [Internet]. [cited 2025 Aug 22]. Available from: https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadApprovalMarketingFDC/FIXED%20DOSE%20COMBINATIONS%20APPROVED%20BY%20DCG%20(I)%20SINCE%201961%20to%2031st%20December%202019.pdf
Liu B, Ji C, Shao Y, Liang T, He J, Jiang H, et al. Etoricoxib decreases subchondral bone mass and attenuates biomechanical properties at the early stage of osteoarthritis in a mouse model. Biomed Pharmacother. 2020;127:110144. PubMed PMID: 32330796
Li B, Yang Z, Li Y, Zhang J, Li C, Lv N. Exploration beyond osteoarthritis: the association and mechanism of its related comorbidities. Front Endocrinol (Lausanne). 2024;15:1352671. PubMed PMID: 3877945
Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019;393:1745-59.
Sellam J, Courties A, Eymard F, Ferrero S, Latourte A, Ornetti P, et al. Recommendations of the french society of rheumatology on pharmacological treatment of knee osteoarthritis. Jt Bone Spine. 2020;87:548-55.
Bruyère O, Cooper C, Pelletier JP, Branco J, Luisa Brandi M, Guillemin F, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014;44:253-63.
Desai SP, Solomon DH, Abramson SB, Buckley L, Crofford LJ, Cosh JJ, et al. Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: An American College of Rheumatology white paper. Arthritis Rheum. 2008;59:1058-73.
Patrício JPH, Barbosa JPP, Ramos RMM, Antunes NFP, de Melo PCS. Relative cardiovascular and gastrointestinal safety of non-selective non-steroidal anti-inflammatory drugs versus cyclo-oxygenase-2 inhibitors: implications for clinical practice. Clin Drug Investig. 2013;33:167-83.
Blandizzi C, Tuccori M, Colucci R, Fornai M, Antonioli L, Ghisu N, Del Tacca M. Role of coxibs in the strategies for gastrointestinal protection in patients requiring chronic non-steroidal anti-inflammatory therapy. Pharmacol Res. 2009;59:90-100.
Laine L, Curtis SP, Langman M, Jensen DM, Cryer B, Kaur A, Cannon CP. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Gastroenterology. 2008;135:1517-25.
Scarpignato C, Lanas A, Blandizzi C, Lems WF, Hermann M, Hunt RH; International NSAID Consensus Group. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med. 2015;13:55. PubMed PMID: 25857826
Moss P, Benson HAE, Will R, Wright A. Fourteen days of etoricoxib 60 mg improves pain, hyperalgesia and physical function in individuals with knee osteoarthritis: a randomized controlled trial. Osteoarthr Cartil. 2017;25:1781-91.
Puopolo A, Boice JA, Fidelholtz JL, Littlejohn TW, Miranda P, Berrocal A, et al. A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis. Osteoarthr Cartil. 2007; 15:1348-56.
Bingham CO, Sebba AI, Rubin BR, Ruoff GE, Kremer J, Bird S, et al. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology. 2007;46:496-507.
Krueger K, Lino L, Dore R, Radominski S, Zhang Y, Kaur A, et al. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: Results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). Ann Rheum Dis. 2008;67:315-22.
van Walsem A, Pandhi S, Nixon RM, Guyot P, Karabis A, Moore RA. Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis. Arthritis Res Ther. 2015;17:66. PubMed PMID: 25879879
Walker C. Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac. Int J Rheumatol. 2018;2018:1302835. PubMed PMID: 30631366
Kean WF, Rainsford KD, Kean IRL. Management of chronic musculoskeletal pain in the Elderly: Opinions on oral medication use. Inflammopharmacology. 2008;16:53-75.
da Costa BR, Reichenbach S, Keller N, Nartey L, Wandel S, Jüni P, et al. Effectiveness of non-steroidal anti- inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2017;390:e21-33.
Biase TMMA, Rocha JGM, Silva MT, Ribeiro-Vaz I, Galvão TF. Renal effects of selective cyclooxygenase-2 inhibitor anti-inflammatory drugs: A systematic review and meta-analysis. Explor Res Clin Soc Pharm. 2024;15:100475. PubMed PMID: 39114538
Agrawal NGB, Rose MJ, Matthews CZ, Woolf EJ, Porras AG, Geer LA, et al. Pharmacokinetics of Etoricoxib in Patients with Hepatic Impairment. J Clin Pharmacol. 2003;43:1136-48.
Kwiatkowska B, Majdan M, Mastalerz-Migas A, Niewada M, Skrzydło-Radomańska B, Mamcarz A. Status of etoricoxib in the treatment of rheumatic diseases. Expert panel opinion. Reumatologia. 2017;55:290-7.
Cochrane DJ, Jarvis B, Keating GM. Etoricoxib. Drugs. 2002;62:2637-51.
Wen ZH, Lin YY, Chang YC, Tang CC, Hsieh SP, Lee HP, et al. The COX-2 inhibitor etoricoxib reduces experimental osteoarthritis and nociception in rats: The roles of TGF-1 and NGF expressions in chondrocytes. Eur J Pain. 2020;24:209-22.
Martina SD, Vesta KS, Ripley TL. Etoricoxib: a highly selective COX-2 inhibitor. Ann Pharmacother. 2005; 39:854-62.
Gratacós J, Martínez-Losa MM, Font P, Montilla C, Fernández-Espartero C, Linares LF, et al. Etoricoxib in ankylosing spondylitis: Is there a role for active patients refractory to traditional NSAIDs? Clin Exp Rheumatol. 2016;34:94-9.
Takemoto JK, Reynolds JK, Remsberg CM, Vega-Villa KR, Davies NM. Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib. Clin Pharmacokinet. 2008;47:703-20.
Schmidt M, Sørensen HT, Pedersen L. Cardiovascular risks of diclofenac versus other older COX-2 inhibitors (Meloxicam and Etodolac) and newer COX-2 inhibitors (Celecoxib and Etoricoxib): a series of nationwide emulated trials. Drug Saf. 2022;45:983-94.
Wan EYF, Yu EYT, Chan L, Mok AHY, Wang Y, Chan EWY, et al. Comparative Risks of Nonsteroidal Anti-inflammatory Drugs on Cardiovascular Diseases: A Population-Based Cohort Study. J Clin Pharmacol. 2023;63:126-34.
Bonnesen K, Pedersen L, Ehrenstein V, Grønkjær MS, Sørensen HT, Hallas J, et al. Impact of Lifestyle and Socioeconomic Position on the Association Between Non-steroidal Anti-inflammatory Drug Use and Major Adverse Cardiovascular Events: A Case-Crossover Study. Drug Saf. 2023;46:533-43.
Klomjit N, Ungprasert P. Acute kidney injury associated with non-steroidal anti-inflammatory drugs. Eur J Intern Med. 2022;101:21-8.
Finckh A, Gilbert B, Hodkinson B, Bae SC, Thomas R, Deane KD, et al. Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol. 2022;18:591-602.
Perera J, Delrosso CA, Nerviani A, Pitzalis C. Clinical Phenotypes, Serological Biomarkers, and Synovial Features Defining Seropositive and Seronegative Rheumatoid Arthritis: A Literature Review. Cells 2024, Vol 13, Page 743. 2024;13:743. PubMed PMID: 38727279
Otón T, Carmona L. The epidemiology of established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2019;33:101477. PubMed PMID: 31987685
Oliver JE, Silman AJ. Why are women predisposed to autoimmune rheumatic diseases? Arthritis Res Ther. 2009;11:1-9.
Woodworth TG, Den Broeder AA. Treating to target in established rheumatoid arthritis: Challenges and opportunities in an era of novel targeted therapies and biosimilars. Best Pract Res Clin Rheumatol. 2015; 29:543-9.
Correction: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82:e76-e76.
Collantes E, Curtis SP, Lee KW, Casas N, McCarthy T, Melian A, et al. A multinational randomized, controlled, clinical trial of etoricoxib inthetreatment of rheumatoid arthritis [ISRCTN25142273]. BMC Fam Pract. 2002;3:1-10.
Kuo FC, Chiang KL, Kao YS. Structural damage and motion rhythm of the spine and hip during trunk lateral bending in ankylosing spondylitis patients with mild to moderate radiographic signs. Clin Biomech. 2019;63:112-8.
Ebrahimiadib N, Berijani S, Ghahari M, Pahlaviani FG. Ankylosing Spondylitis. J Ophthalmic Vis Res. 2021;16: 462-469.
Pedersen SJ, Maksymowych WP. The Pathogenesis of Ankylosing Spondylitis: an Update. Curr Rheumatol Rep. 2019;21:1-10.
Bilski R, Kamiński P, Kupczyk D, Jeka S, Baszyński J, Tkaczenko H, et al. Environmental and Genetic Determinants of Ankylosing Spondylitis. Int J Mol Sci 2024, Vol 25, Page 7814. 2024;25:7814. PubMed PMID: 39063056
Agrawal P, Tote S, Sapkale B. Diagnosis and treatment of ankylosing spondylitis. Cureus. 2024;16(1): e52559 PubMed PMID: 38371049
Braun J. Correspondence on “ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.” Ann Rheum Dis. 2023;82: e205-e205.
da Cruz Lage R, Marques CDL, Oliveira TL, Resende GG, Kohem CL, Saad CG, et al. Brazilian recommendations for the use of nonsteroidal anti-inflammatory drugs in patients with axial spondyloarthritis. Adv Rheumatol. 2021;61:1-21.
Wang R, Dasgupta A, Ward MM. Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: A Bayesian network meta-analysis of clinical trials. Ann Rheum Dis. 2016;75:1152-60.
Jansen JP, Taylor SD. Cost-Effectiveness Evaluation of Etoricoxib versus Celecoxib and Nonselective NSAIDs in the Treatment of Ankylosing Spondylitis in Norway. Int J Rheumatol. 2011;2011:160326. PubMed PMID: 21772851
Parthasarathy P, Vivekanandan S. Urate crystal deposition, prevention and various diagnosis techniques of GOUT arthritis disease: a comprehensive review. Heal Inf Sci Syst. 2018;6:1-13.
McCarty DJ. Crystals and arthritis. Disease-a-Month. 1994;40:258-99.
Zhang W zheng. Uric acid en route to gout. Adv Clin Chem. 2023;116:209-75.
Lin X, Wang X, Li X, Song L, Meng Z, Yang Q, et al. Gender- and Age-Specific Differences in the Association of Hyperuricemia and Hypertension: A Cross-Sectional Study. Int J Endocrinol. 2019;2019:7545137. PubMed PMID: 30944567
Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020;16:380-90.
Martins D, Tonon CR, Pacca RL, Matchil NL, Junior LAJ, Queiroz DS, et al. Gout Storm. Am J Case Rep. 2021;22:e932683. PubMed PMID: 34855717
Kumar M, Manley N, Mikuls TR. Gout flare burden, diagnosis, and management: navigating care in older patients with comorbidity. Drugs and Aging. 2021; 38:545-57.
Pillinger MH, Mandell BF. Therapeutic approaches in the treatment of gout. Semin Arthritis Rheum. 2020; 50:S24-30.
Kiltz U, Smolen J, Bardin T, Cohen Solal A, Dalbeth N, Doherty M, et al. Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis. 2017;76:632-8.
Li M, Yu C, Zeng X. Correction: Comparative efficacy of traditional non-selective NSAIDs and selective cyclo-oxygenase-2 inhibitors in patients with acute gout: a systematic review and meta-analysis. BMJ Open. 2020;10:e036748corr1. PubMed PMID: 33055126
Rubin BR, Burton R, Navarra S, Antigua J, Londoño J, Pryhuber KG, et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: A randomized controlled trial. Arthritis Rheum. 2004;50:598-606.
Schumacher HR, Boice JA, Daikh DI, Mukhopadhyay S, Malmstrom K, Ng J, et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ. 2002;324:1488-92.
Brooks P, Kubler P. Etoricoxib for arthritis and pain management. Ther Clin Risk Manag. 2006;2:45-57.
Moore PA, Ziegler KM, Lipman RD, Aminoshariae A, Carrasco-Labra A, Mariotti A. Benefits and harms associated with analgesic medications used in the management of acute dental pain: An overview of systematic reviews. J Am Dent Assoc. 2018;149:256-265.e3. PubMed PMID: 29599019
Malmstrom K, Sapre A, Coughlin H, Agrawal NGB, Mazenko RS, Fricke JR. Etoricoxib in acute pain associated with dental surgery: A randomized, double-blind, placebo- and active comparator-controlled dose-ranging study. Clin Ther. 2004;26:667-79.
La Rosa G, Consoli M, Abiad R, Toscano A, Pedullà E. Comparing pre- and postoperative etoricoxib administration versus only postoperative on third molar extraction sequelae and oral health quality of life: a prospective quasi-experimental study. Clin Oral Investig. 2024;28:218. PubMed PMID: 38489136
Al-Mukhtar YH, Deleme ZH, Khudhur AS. Evaluating the efficacy of Etoricoxib in reducing post-operative pain associated with minor oral surgery. A randomized clinical trial. Brazilian Dent Sci. 2023;26.
la Torre LF, Franco-González DL, Brennan-Bourdon LM, Molina-Frechero N, Alonso-Castro ÁJ, Isiordia-Espinoza MA. Analgesic Efficacy of Etoricoxib following Third Molar Surgery: A Meta-analysis. Behav Neurol. 2021;2021:9536054. PubMed PMID: 34539935
Machado GC, Abdel-Shaheed C, Underwood M, Day RO. Non-steroidal anti-inflammatory drugs (NSAIDs) for musculoskeletal pain. BMJ. 2021;372:n104. PubMed PMID: 33514562
Zuqui-Ramírez MA, Belalcazar-López VM, Urenda-Quezada A, González-Rebatu Y González A, Sander-Padilla JG, Lugo-Sánchez LA, et al. Multimodal analgesia approach in acute low back pain management: a phase III study of a novel analgesic combination of etoricoxib/tramadol. Pain Ther. 2024 Dec;13:1511-28.
Romanenko V. Evaluation of analgetic properties of etoricoxib and lornoxicam and their effect on central sensitization in chronic low back pain. Pain Joints Spine. 2022;12:30-9.
Shetty U, Neema P, Muthu S, Bhojwani D, Muchhala S, Shetty UK, et al. Nationwide etoricoxib injection clinical experience (NICE): real-world evidence in indian patients. Cureus. 2024;16:e54020. PubMed PMID: 38476812
Xie L, Li Z, Shang ZJ. Preemptive oral etoricoxib on health-related quality of life after mandibular third molar surgery: a randomized, double-blind, placebo-controlled clinical trial. Biomed Res Int. 2021; 2021:8888151. PubMed PMID: 33748282.
Mubarak HA, Al-Adily SS. A Randomized case-controlled clinical trial of the effect of preemptive etoricoxib, prednisolone and a control group on of postoperative sequelae after surgical removal of impacted mandibular third molars. Med Leg Updat. 2021;21:563-71.
Sivapornpan S, Punyashthira A, Chantawong N, Wisarnsirirak P, Maireang K, Thaweekul Y, et al. The efficacy of oral etoricoxib in pain control during colposcopy-directed cervical biopsy: a randomized control trial. Asian Pac J Cancer Prev. 2023;24:2855-9.
Weraarchakul S, Sae-Jung S. Etoricoxib can reduce post-operative morphine consumption and pain score in patients undergoing lumbar laminectomy compare to acetaminophen: a randomized trial. Glob Spine J. 2023;13:1433-40.
Porat D, Dukhno O, Partook-Maccabi M, Vainer E, Cvijić S, Dahan A. Selective COX-2 inhibitors after bariatric surgery: celecoxib, etoricoxib and etodolac post-bariatric solubility/dissolution and pharmacokinetics. Int J Pharm. 2023;645:123347. PubMed PMID: 37633536
Cionac Florescu S, Anastase DM, Munteanu AM, Stoica CI. Postoperative etoricoxib versus ketoprofen administration for pain management after total knee arthroplasty: a randomized, double-blind controlled study. J Anesthesiol. 2015;2015:1-6.
Zhang J, Gao HF, Yang C, Zhu T, Ji F, Yang M, et al. Prevention of taxane-associated acute pain syndrome with etoricoxib for patients with breast cancer: A phase II randomised trial. Eur J Cancer. 2022;171:150-60.
Garza-Ocañas L, Badillo-Castaneda CT, Montoya Eguía SL, Zanatta-Calderón MT, Torres Garza JD, Vinicio Gómez-Meza M, et al. Comparative bioavailability of a novel fixed-dose combination etoricoxib and tramadol. Orig Artic Clin Pharmacol Drug Dev. 2024;2024:1253-9.
Kuźmińska J, Sobczak A, Majchrzak-Celińska A, Żółnowska I, Gostyńska A, Jadach B, et al. Etoricoxib-Cannabidiol combo: potential role in glioblastoma treatment and development of PLGA-Based Nanoparticles. Pharmaceutics. 2023;15:2104. PubMed PMID: 37631318
Taha EF, Hamed NS, Khateeb S. Etoricoxib nanostructured lipid carriers attenuate inflammation by modulating Cyclooxygenase-2 signaling and activation of nuclear factor-B-p65 pathways in radiation-induced acute cardiotoxicity in rats. Eur J Pharmacol. 2023;957:176029. PubMed PMID: 37648012
Mijailovic I, Janjic B, Milicic B, Todorovic A, Ilic B, Misic T, et al. Comparison of preemptive etoricoxib and dexamethasone in third molar surgery - a randomized controlled clinical trial of patient-reported and clinical outcomes. Clin Oral Investig. 2023;27:5263-73.
Saroj K, Haresh B, Yogendra P. A randomized double-blind comparative study of efficacy and safety between low-dose etoricoxib and ibuprofen coadministered with low-dose paracetamol for dental pain. J Pharmacol Pharmacother. 2022;13:79-84.
Karmakar A, Arora S, Singal R, Mitra S, Gitika, Saha M, et al. The efficacy and safety of a combination of thiocolchicoside and etoricoxib in low back pain (ESCoTEL): a randomized active-controlled trial. Cureus. 2023;15:e47621. PubMed PMID: 38021944
Yeole AB, Sree Ranga Lakshmi G, Selvakumar CJ, Goni VG, Nawal CL, Valya BJ, et al. Efficacy and safety of pregabalin prolonged release-etoricoxib combination compared to etoricoxib for chronic low back pain: phase 3, randomized study. Pain Ther. 2022;11: 1451-69.
Mitra S, Ahuja V, Garg S. Analgesic efficacy of etoricoxib versus ibuprofen in unilateral hip or knee arthroplasty: an open-label randomized trial. Res Opin Anesth Intensive Care. 2022;9:145-51.
Naringrekar S, Mamtora J. Assessment of the effect of calcium on the anti-inflammatory activity of etoricoxib in albino rats. Int J Basic Clin Pharmacol. 2021;10:683-8.
Abd El-Kader M, Taha RI. Comparative nephroprotective effects of curcumin and etoricoxib against cisplatin-induced acute kidney injury in rats. Acta Histochem. 2020;122:151534. PubMed PMID: 32151374
Peerananrangsee S, Thamkhantho M. Effectiveness of etoricoxib 120 mg in pain relief during iud insertion: A randomized, double-blind, placebo controlled clinical trial. J Med Assoc Thail. 2018;101:1-6.
Cannon CP, Curtis SP, Bolognese JA, Laine L. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) Study Program: Cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. Am Heart J. 2006;152:237-45.
Chang DJ, Desjardins PJ, King TR, Erb T, Geba GP. The analgesic efficacy of etoricoxib compared with oxycodone/acetaminophen in an acute postoperative pain model: A randomized, double-blind clinical trial. Anesth Analg. 2004;99:807-15.
Steffens JP, Santos FA, Sartori R, Pilatti GL. Preemptive dexamethasone and etoricoxib for pain and discomfort prevention after periodontal surgery: a double‐masked, crossover, controlled clinical trial. J Periodontol. 2010;81:1153-60.
Isola G, Matarese G, Alibrandi A, Dalessandri D, Migliorati M, Pedullà E, et al. Comparison of effectiveness of etoricoxib and diclofenac on pain and perioperative sequelae after surgical avulsion of mandibular third molars: A randomized, controlled, clinical trial. Clin J Pain. 2019;35:908-15.
Steffens JP, Santos FA, Pilatti GL. The use of etoricoxib and celecoxib for pain prevention after periodontal surgery: a double‐masked, parallel‐group, placebo‐controlled, randomized clinical trial. J Periodontol. 2011;82:1238-44.
Matsumoto AK, Melian A, Mandel DR, McIlwain HH, Borenstein D, Zhao PL, et al. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol. 2002;29:1623-30.
Zardo LN, Santos FA, Pilatti GL. Use of etoricoxib and dexamethasone for postoperative pain prevention and control in mucogingival surgery: a randomized parallel double-blind clinical trial. Brazilian Journal of Oral Sciences. 2013;12:345-51.
Kvien TK, Greenwald M, Peloso PM, Wang H, Mehta A, Gammaitoni A. Do COX-2 inhibitors provide additional pain relief and anti-inflammatory effects in patients with rheumatoid arthritis who are on biological disease-modifying anti-rheumatic drugs and/or corticosteroids? Post-hoc analyses from a randomized clinical trial with etoricoxib. BMC Musculoskelet Disord. 2015;16:26. PubMed PMID: 25886874
Balazcs E, Sieper J, Bickham K, Mehta A, Frontera N, Stryszak P, et al. A randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib versus naproxen in patients with ankylosing spondylitis. BMC Musculoskelet Disord. 2016;17:1-12.
Xie L, Sang L, Li Z. Does low dose of etoricoxib play pre-emptive analgesic effect in third molar surgery? A randomized clinical trial. BMC Oral Health. 2021;21:462. PubMed PMID: 34556118
Ramey DR, Watson DJ, Yu C, Bolognese JA, Curtis SP, Reicin AS. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: An updated combined analysis. Curr Med Res Opin. 2005;21:715-22.
Schreiber K, Frishman M, Russell MD, Dey M, Flint J, Allen A, et al. British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: comorbidity medications used in rheumatology practice. Rheumatology. 2023;62:e89-104.
Munir MA, Enany N, Zhang JM. Nonopioid analgesics. Med Clin North Am. 2007;91:97-111.
Tripathy S, Dash SC. Etoricoxib-induced life-threatening hyperkalemia and acute kidney dysfunction against the background of telmisartan and a low sodium diet. Int J Emerg Med. 2010;3:443-6.
Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: Bridging a gap between clinical trials and clinical practice. Ann Rheum Dis. 2010;69:374-9.
Song GG, Seo YH, Kim JH, Choi SJ, Ji JD, Lee YH. Relative Wirksamkeit und Verträglichkeit von Etoricoxib, Celecoxib und Naproxen bei der Behandlung von Osteoarthritis: Eine bayessche Netzwerkmetaanalyse randomisiert-kontrollierter Studien auf Basis von Patientenausschlüssen. Z Rheumatol. 2016;75:508-16.
Zhang S, Zhang Y, Liu P, Zhang W, Ma J lin, Wang J. Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis. Clin Rheumatol. 2016;35:151-8.
Qiu J, Xie M, Qu R. The influence of etoricoxib on pain control for laparoscopic cholecystectomy: a meta-analysis of randomized controlled trials. Surg Laparosc Endosc Percutaneous Tech. 2019;29:150-4.
Moore RA, Straube S, Paine J, Derry S, McQuay HJ. Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: Examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction. Pain. 2011;152:982-9.
Lin TM, Chi JE, Chang CC, Kang YN. Do etoricoxib and indometacin have similar effects and safety for gouty arthritis? A meta-analysis of randomized controlled trials. J Pain Res. 2018;12:83-91.
Feng X, Tian M, Zhang W, Mei H. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis. PLoS One. 2018;13:e0190798. PubMed PMID: 29320568.
Kim D, Cho SK, Nam SW, Kwon HH, Jung SY, Jeon CH, et al. Cardiovascular and gastrointestinal effects of etoricoxib in the treatment of osteoarthritis: a systematic review and network meta-analysis. J Rheum Dis. 2017;24:293-303.
Ahmadi M, Bekeschus S, Weltmann KD, von Woedtke T, Wende K. Non-steroidal anti-inflammatory drugs: recent advances in the use of synthetic COX-2 inhibitors. RSC Med Chem. 2022;13:471-96.
Shetty U, Neema P, Muthu S, Bhojwani D, Muchhala S. Nationwide Etoricoxib Injection Clinical Experience (NICE): Real-World Evidence in Indian Patients. Cureus. 2024;16(2):e54020. PubMed PMID: 38476812
Abdelall AMA, Khames A, Bekhit AA, Fathy M. Potential Effect of Etoricoxib in Reducing Inflammation in Methotrexate-Induced Pulmonary Injury in Rats: Role of Oxidative Stress and the TLR4/p38-MAPK/NF-B Signaling Pathway. Inflammation. 2025;48:2407-16.
